Results 131 to 140 of about 82,921 (179)

Prevention of Subsequent L-Asparaginase Hypersensitivity in Children Through Premedication: A Single-Center Experience. [PDF]

J Pediatr Pharmacol Ther
Saligupta P, Choed-Amphai C, Sathitsamitphong L, Lao-Araya M.   +3 more
europepmc   +1 more source

Single-center analysis of relapse risk factors and prognosis in 256 cases of ETV6::RUNX1-positive pediatric acute lymphoblastic leukemia. [PDF]

BMC Pediatr
Hu B, Hu F, He H, Kong L.
europepmc   +1 more source

Cysteine Pegylation of a Mutant L-asparaginase Affords Enhanced Activity and Thermostability. A Comparative Study Against N-terminal Conjugation. [PDF]

Appl Biochem Biotechnol
Ferraro RB, Benevides GR, Rabelo J, da Silva Chaves F, Ruiz-Lara GV, Carretero G, Monteiro G, Pessoa-Junior A, Converti A, Lynham S, Long PF, Rangel-Yagui CO.   +11 more
europepmc   +1 more source

Enzyme therapy in a structural light. [PDF]

IUCrJ
Cooper J.
europepmc   +1 more source

Relapse risk and outcome of discontinuing asparaginase in children with acute lymphoblastic leukemia. [PDF]

Ann Hematol
Wang X, Liu C, Chen Y, Wang J, Wan Y, An W, Li X, Liu L, Liu F, Hu T, Zhang Y, Zhang L, Zou Y, Chen X, Chen Y, Guo Y, Zhu X, Yang W.   +17 more
europepmc   +1 more source

2 cases of pegylated asparaginase-associated cerebral venous sinus thrombosis in children: clinical analysis and literature review. [PDF]

Thromb J
Chen M, Lu G, Huang Y, Hu Z.
europepmc   +1 more source

Biogeneric native and polyethylene glycol-conjugated E. coli asparaginases for treating children with acute lymphoblastic leukaemia

Datta N, Jana B, Goswami S, Roy A, Samaddar S, Kundu S, Gogoi MP, Dasgupta B, Dutta T, Das N, Saha V, Sidhu J, Krishnan S.   +12 more
europepmc   +1 more source

Genetic predisposition to PEG‐asparaginase hypersensitivity in children treated according to NOPHO ALL2008 [PDF]

British Journal of Haematology, 2019
Asparaginase is essential in childhood acute lymphoblastic leukaemia (ALL) treatment, however hypersensitivity reactions to pegylated asparaginase (PEG-asparaginase) hampers anti-neoplastic efficacy.
Goda Vaitkevičienė, Ramneek Gupta, Mats Heyman   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

L-Asparaginase and PEG Asparaginase— Past, Present, and Future

Leukemia and Lymphoma, 1993
L-asparaginase is an enzyme which hydrolyses asparagine. Since the 1960s it has been known that some leukemic cells are deficient in asparagine synthetase and therefore cannot manufacture sufficient quantities of this essential amino acid to maintain cell viability.
Susan Lerner, M J Keating
exaly   +3 more sources

PEG‐asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol [PDF]

Pediatric Blood & Cancer, 2014
BackgroundL‐Asparaginase is an effective drug in the treatment of childhood acute lymphoblastic leukemia (ALL). The use of L‐asparaginase may be limited by serious adverse events of which allergy is the most frequent. The objective of this study was to describe the clinical aspects of PEG‐asparaginase allergy in children treated according to the Nordic
Henriksen, Louise Tram, Harila-Saari, Arja, Ruud, Ellen, Abrahamsson, Jonas, Pruunsild, Kaie, Vaitkeviciene, Goda, Jónsson, Ólafur Gísli, Schmiegelow, K., Heyman, Mats, Schrøder, Henrik, Albertsen, Birgitte Klug   +10 more
openaire   +4 more sources